Novel treatment strategies for aggressive non-Hodgkin's lymphoma.
The World Health Organization has included different types of lymphoma under the aggressive category. In the US, diffuse large B-cell lymphoma is the most common aggressive lymphoma and accounts for > 30% of the 55,000 new cases diagnosed annually. Recent advances in the knowledge of the molecular biology have provided an increased understanding of the heterogeneity of non-Hodgkin's lymphoma. New treatments, especially those with the use of monoclonal antibodies, are improving both the survival and the response rate.
Department of Lymphoma/Myeloma, University of Texas, MD Anderson Cancer Center, Box # 429, Houston, TX 77030, USA.
Luis
L
Fayad
Anas
A
Younes
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism
D000970:Antineoplastic Agents